Becton, Dickinson and Company's Waters Transaction Can Unlock Value, RBC Says

MT Newswires Live
Sep 25, 2025

Becton, Dickinson and Company (BDX) executing a $17.5 billion transaction, under which the company is spinning off and merging its Biosciences and Diagnostics businesses with Waters (WAT), could unlock value, said RBC in a Thursday note.

The company is positioning itself for its next growth phase, RBC said, adding that the new life science tools and diagnostics company could drive upside for the shareholders with about $345 million in annualized earnings before interest, taxes, depreciation, and amortization synergies by year five.

The new company is poised for 3% to 3.5% year-on-year organic growth in fiscal 2026 and operating margins similar to 2025 that may limit earnings per share growth in the year, with more consistent high single-digit growth expected in fiscal 2027 and beyond, RBC said.

The firm initiated coverage on Becton, Dickinson and Company with a sector perform and $211 price target.

Price: 179.40, Change: -6.66, Percent Change: -3.58

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10